Faraaz Ali Shah1,2, Hussain Mahmud3, Teresa Gallego-Martin1, Michael J Jurczak3, Christopher P O'Donnell1, Bryan J McVerry1,4. 1. Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 2. Veteran Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. 3. Division of Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, Pennsylvania. 4. Center for Medicine and the Microbiome, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Sepsis, a complex disorder characterized by a dysregulated immune response to an inciting infection, affects over one million Americans annually. Dysglycemia during sepsis hospitalization confers increased risk of organ dysfunction and death, and novel targets for the treatment of sepsis and maintenance of glucose homeostasis are needed. Incretin hormones are secreted by enteroendocrine cells in response to enteral nutrients and potentiate insulin release from pancreatic β cells in a glucose-dependent manner, thereby reducing the risk of insulin-induced hypoglycemia. Incretin hormones also reduce systemic inflammation in preclinical studies, but studies of incretins in the setting of sepsis are limited. METHODS: In this bench-to-bedside mini-review, we detail the evidence to support incretin hormones as a therapeutic target in patients with sepsis. We performed a PubMed search using the medical subject headings "incretins," "glucagon-like peptide-1," "gastric inhibitory peptide," "inflammation," and "sepsis." RESULTS: Incretin-based therapies decrease immune cell activation, inhibit proinflammatory cytokine release, and reduce organ dysfunction and mortality in preclinical models of sepsis. Several small clinical trials in critically ill patients have suggested potential benefit in glycemic control using exogenous incretin infusions, but these studies had limited power and were performed in mixed populations. Further clinical studies examining incretins specifically in septic populations are needed. CONCLUSIONS: Targeting the incretin hormone axis in sepsis may provide a means of not only promoting euglycemia in sepsis but also attenuating the proinflammatory response and improving clinical outcomes. Published by Oxford University Press on behalf of the Endocrine Society 2019.
BACKGROUND:Sepsis, a complex disorder characterized by a dysregulated immune response to an inciting infection, affects over one million Americans annually. Dysglycemia during sepsis hospitalization confers increased risk of organ dysfunction and death, and novel targets for the treatment of sepsis and maintenance of glucose homeostasis are needed. Incretin hormones are secreted by enteroendocrine cells in response to enteral nutrients and potentiate insulin release from pancreatic β cells in a glucose-dependent manner, thereby reducing the risk of insulin-induced hypoglycemia. Incretin hormones also reduce systemic inflammation in preclinical studies, but studies of incretins in the setting of sepsis are limited. METHODS: In this bench-to-bedside mini-review, we detail the evidence to support incretin hormones as a therapeutic target in patients with sepsis. We performed a PubMed search using the medical subject headings "incretins," "glucagon-like peptide-1," "gastric inhibitory peptide," "inflammation," and "sepsis." RESULTS: Incretin-based therapies decrease immune cell activation, inhibit proinflammatory cytokine release, and reduce organ dysfunction and mortality in preclinical models of sepsis. Several small clinical trials in critically ill patients have suggested potential benefit in glycemic control using exogenous incretin infusions, but these studies had limited power and were performed in mixed populations. Further clinical studies examining incretins specifically in septic populations are needed. CONCLUSIONS: Targeting the incretin hormone axis in sepsis may provide a means of not only promoting euglycemia in sepsis but also attenuating the proinflammatory response and improving clinical outcomes. Published by Oxford University Press on behalf of the Endocrine Society 2019.
Authors: Lorène J Lebrun; Kaatje Lenaerts; Dorien Kiers; Jean-Paul Pais de Barros; Naig Le Guern; Jiri Plesnik; Charles Thomas; Thibaut Bourgeois; Cornelis H C Dejong; Matthijs Kox; Inca H R Hundscheid; Naim Akhtar Khan; Stéphane Mandard; Valérie Deckert; Peter Pickkers; Daniel J Drucker; Laurent Lagrost; Jacques Grober Journal: Cell Rep Date: 2017-10-31 Impact factor: 9.423
Authors: Michael Y Lee; Jonathan D Fraser; Marianne J Chapman; Krishnaswamy Sundararajan; Mahesh M Umapathysivam; Matthew J Summers; Antony V Zaknic; Christopher K Rayner; Juris J Meier; Michael Horowitz; Adam M Deane Journal: Diabetes Care Date: 2013-07-08 Impact factor: 19.112
Authors: Adam M Deane; Marianne J Chapman; Robert J L Fraser; Carly M Burgstad; Laura K Besanko; Michael Horowitz Journal: Crit Care Date: 2009-05-13 Impact factor: 9.097
Authors: Javier T Gonzalez; Marlou L Dirks; Andrew M Holwerda; Imre W K Kouw; Luc J C van Loon Journal: Eur J Appl Physiol Date: 2020-07-10 Impact factor: 3.078